Fulfilling the potential of real-world evidence for lung cancer in Canada

Autor Cheema, P.K., Kuruvilla, S.
Vydáno v Curr Oncol (2019)

Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer

Autor Cheema, P.K., Burkes, R.L.
Vydáno 2013

The neurotoxicity of β-N-oxalyl-l-αβ-diaminopropionic acid, the neurotoxin from the pulse Lathyrus sativus

Autor Cheema, P. S., Malathi, K., Padmanaban, G., Sarma, P. S.
Vydáno 1969

Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer

Autor Cheema, P.K., Rothenstein, J., Melosky, B., Brade, A., Hirsh, V.
Vydáno v Curr Oncol (2019)

International variability in the reimbursement of cancer drugs by publically funded drug programs

Autor Cheema, P.K., Gavura, S., Migus, M., Godman, B., Yeung, L., Trudeau, M.E.
Vydáno 2012

Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer

Autor Melosky, B., Banerji, S., Blais, N., Chu, Q., Juergens, R., Leighl, N.B., Liu, G., Cheema, P.
Vydáno v Curr Oncol (2020)

Evidence-based best practices for EGFR T790M testing in lung cancer in Canada

Autor Stockley, T., Souza, C.A., Cheema, P.K., Melosky, B., Kamel-Reid, S., Tsao, M.S., Spatz, A., Karsan, A.
Vydáno v Curr Oncol (2018)

Consensus recommendations for optimizing biomarker testing to identify and treat advanced EGFR-mutated non-small-cell lung cancer

Autor Cheema, P.K., Gomes, M., Banerji, S., Joubert, P., Leighl, N.B., Melosky, B., Sheffield, B.S., Stockley, T., Ionescu, D.N.
Vydáno v Curr Oncol (2020)

Standardizing biomarker testing for Canadian patients with advanced lung cancer

Autor Melosky, B., Blais, N., Cheema, P., Couture, C., Juergens, R., Kamel-Reid, S., Tsao, M.-S., Wheatley-Price, P., Xu, Z., Ionescu, D.N.
Vydáno v Curr Oncol (2018)

Rate of EGFR mutation testing for patients with nonsquamous non-small-cell lung cancer with implementation of reflex testing by pathologists

Autor Cheema, P.K., Raphael, S., El-Maraghi, R., Li, J., McClure, R., Zibdawi, L., Chan, A., Victor, J.C., Dolley, A., Dziarmaga, A.
Vydáno v Curr Oncol (2017)

A network approach to developing immuno-oncology combinations in Canada

Autor Higenell, V., Fajzel, R., Batist, G., Cheema, P.K., McArthur, H.L., Melosky, B., Morris, D., Petrella, T.M., Sangha, R., Savard, M.F., Sridhar, S.S., Stagg, J., Stewart, D.J., Verma, S.
Vydáno v Curr Oncol (2019)

Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer

Autor Laurie, S.A., Banerji, S., Blais, N., Brule, S., Cheema, P.K., Cheung, P., Daaboul, N., Hao, D., Hirsh, V., Juergens, R., Laskin, J., Leighl, N., MacRae, R., Nicholas, G., Roberge, D., Rothenstein, J., Stewart, D.J., Tsao, M.S.
Vydáno v Curr Oncol (2019)

Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer

Autor Melosky, B., Agulnik, J., Albadine, R., Banerji, S., Bebb, D.G., Bethune, D., Blais, N., Butts, C., Cheema, P., Cheung, P., Cohen, V., Deschenes, J., Ionescu, D.N., Juergens, R., Kamel-Reid, S., Laurie, S.A., Liu, G., Morzycki, W., Tsao, M.S., Xu, Z., Hirsh, V.
Vydáno v Curr Oncol (2016)

Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer

Autor Melosky, B., Cheema, P., Agulnik, J., Albadine, R., Bebb, D.G., Blais, N., Burkes, R., Butts, C., Card, P.B., Chan, A.M.Y., Hirsh, V., Ionescu, D.N., Juergens, R., Morzycki, W., Poonja, Z., Sangha, R., Tehfe, M., Tsao, M.S., Vincent, M., Xu, Z., Liu, G.
Vydáno v Curr Oncol (2018)